Tissue Doppler Imaging as a predictor of therapy-related cardiac dysfunction in breast cancer patients

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Piñeiro Lamas, Beatriz
Lesta-Mellid, Rocío
Bouzas-Mosquera, Alberto
Barbeito Caamaño, Cayetana

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Piñeiro-Lamas, B., López-Cheda, A., Cao, R. et al. Tissue Doppler Imaging as a predictor of therapy-related cardiac dysfunction in breast cancer patients. Int J Cardiovasc Imaging 41, 1505–1512 (2025). https://doi.org/10.1007/s10554-025-03439-1

Type of academic work

Academic degree

Abstract

[Abstract]: Although early detection and prediction of cancer therapy-related cardiac dysfunction (CTRCD) have been widely studied in the literature in breast cancer patients, little is known about the potential predictive role of Tissue Doppler Imaging (TDI) as a risk factor. The purpose of this study is to assess the predictive role of Pulsed-waved TDI in predicting car¬diotoxicity in breast cancer patients. In total, 270 breast cancer patients, 27 of whom experienced CTRCD during the follow-up period, were enrolled. Echocardiography was performed at baseline (before the beginning of the treatment), and TDI images were obtained. Other clinical variables were also measured. Significant differences were found between the TDI images of patients who developed cardiotoxicity and those of patients who did not, particularly around the E′ wave. Specifically, patients with CTRCD had a smoother and later E′ wave. The variable vE′ , which accounts for both the peak velocity of the E′ wave and the timing within the cardiac cycle when this peak is reached, was found to be highly informative. Patients with a vE′ value above the threshold of 0.052 have a higher risk of CTRCD, which supports its potential as an early indicator of the risk of cardiotoxicity. The vE′ in the baseline TDI is significantly associated with the CTRCD. Specific characteristics of the E′ wave, such as the moment in the cycle when its peak occurs and its veloc¬ity, may be used in clinical practice to predict cardiovascular side effects in patients undergoing breast cancer treatment.

Description

Rights

Attribution 4.0 International
Attribution 4.0 International

Except where otherwise noted, this item's license is described as Attribution 4.0 International